EirGenix Inc.

6589

TW0006589005

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
83.1 ^TWD	+2.34%		+4.01%	-17.31%

Mar. 22	EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 08	EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	CI

National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System

September 18, 2023 at 01:34 am EDT

EirGenix Inc.'s biosimilar, Eirgasun vial 150 mg, has been approved by National Health Insurance Administration, Ministry of Health and Welfare to be enrolled in the reimbursement system, it is officially effective from October 1, 2023. Usage: The treatment of HER2 overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric cancer. The price paid is TWD 11,323 per vial at the current market price.

Latest news about EirGenix Inc.

EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	Mar. 08	CI
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC	Nov. 22	CI
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
EirGenix Inc. Announces the Establishment of Phase II Facility and Production Equipment in Zhubei	Nov. 09	CI
Novartis' Sandoz Unit Says European Medicines Agency Panel Supports Approval of Trastuzumab Biosimilar	23-09-18	MT
Novartis Cancer Drug Gets Marketing Recommendation from European Medicines Agency	23-09-18	DJ
Novartis Unit Wins European Medicines Agency's Positive Opinion for Breast Cancer Biosimilar	23-09-18	MT
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System	23-09-18	CI
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
EirGenix Inc. Completes the Phase 1 Clinical Trial of Its Second Breast Cancer Biosimilar EG1206A in Europe	23-05-02	CI
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
EirGenix Inc. announced a financing transaction	23-03-09	CI
EirGenix Inc. Announces Executive Changes	23-01-10	CI
Eirgenix Inc. Announces Establishment of Corporate Governance Committee	22-12-28	CI
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Eirgenix, Inc., Submits the Biosimilar Drug Eirgasum of 150 Mg Powder for Concentratefor Solution for Infusion Presentation New Drug Application to the Taiwan Food and Drug Administration	22-09-30	CI
EirGenix Inc. Appoints Po-Chih Chen as Remuneration Committee	22-09-08	CI
EirGenix Inc. Announces Board Changes	22-09-07	CI
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
EirGenix Inc. Announces Production Line Expansion and Production Equipment at Zhubei Facility	22-08-11	CI
EirGenix Inc. Announces Management Changes	22-06-10	CI
EirGenix Inc. Announces Board Appointments	22-06-10	CI
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI

Chart EirGenix Inc.

Duration

Period

More charts

Company Profile

EirGenix Inc is a Taiwan-based company primarily engaged in the development of antibody drugs and the manufacture of biopharmaceuticals. Its main businesses include the provision of Contract Development & Manufacturing Organization (CDMO) services, the construction of cell strain, the manufacture of clinical trial medicine, analytical science and protein identification, and PIC/S manufacturing plant to provide clinical trial drug production.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for EirGenix Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

83.1 TWD

Average target price

132.5 TWD

Spread / Average Target

+59.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
EIRGENIX INC.	-17.31%	790M
CSL LIMITED	-3.05%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
UCB	+60.01%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.79B

Biopharmaceuticals

EirGenix Inc.

Equities

6589

TW0006589005

Pharmaceuticals

National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System

EPS Revisions